Login / Signup

Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trials.

Keizo KanasakiShen QuFumiko YamamotoCornelia SchepersRafael Sani SimõesDaisuke YabeLinong Ji
Published in: Expert opinion on drug safety (2021)
Linagliptin is well tolerated in Asian T2D patients, including East Asians, with low risk for AEs.
Keyphrases
  • placebo controlled
  • double blind
  • clinical trial
  • phase iii
  • phase ii
  • open label
  • study protocol
  • newly diagnosed
  • end stage renal disease
  • phase ii study
  • ejection fraction
  • prognostic factors
  • radiation therapy